Archive | April, 2015

Dr. Michael Har-Noy Discusses the “Mirror EffectTM” – A Novel Cancer Treatment

25 Apr

Dr. Michael Har-Noy, CEO of Immunovative Therapies, Ltd., says that the “Mirror EffectTM” is an immune reaction that addresses the problem of uncoupling the curative graft versus tumor (GVT) effect of an allogeneic bone marrow transplant (BMT) from the deadly graft versus host disease (GVHD) side effect.

Dr. Michael Har-Noy says that he solved this problem by designing a T-cell infusion that mimicked the immune cascade caused by the transplanted donor cells but that was controlled by the immune mechanism of the patient.   This process, termed the “Mirror EffectTM”, could potentially recreate the curative effect of a BMT without the deadly side effects.

The Mirror EffectTM treatment, says Dr. Michael Har-Noy, reverses the closely linked GVT and GVHD mechanisms that come from the infused bone marrow graft. This effect thus stems from the host rather than from transplanted cells, thus causing a host versus tumor (HVT) response that is closely linked to the benign host versus graft (HVG) rejection. To initiate the Mirror EffectTM, normal T-cells are infused into a cancer patient. These cells then cause the patient’s own immune cells to attack the cancer (HVT effect) and cause an inflammatory reaction which neutralizes the immunoavoidance mechanisms of the cancer.

Dr. Michael Har-Noy indicates that since the HVT mechanism must be linked to a HVG rejection, the patient needs an immune system that is strong enough to reject the donor T-cells. Also, since graft rejection (HVG) is required, the donor cells need to be mismatched to the recipient. This is an immense improvement over allogeneic BMT, where only one third of eligible patients can find an appropriately matched donor.

The Mirror EffectTM therefore involves administration of unmatched cells into a cancer patient who has not been pretreated, so that these foreign cells can be rejected by the patient’s immune system. Dr. Michael Har-Noy says that this HVG mechanism is the “mirror” of the deadly GVHD but is not harmful. The HVG rejection starts the host-mediated tumor destruction (HVT), which is the “mirror” of the GVT mechanism. The “mirror” effect mimics the curative GVT mechanism of BMT while at the same time avoiding the deadly toxicity of GVHD.

Dr. Michael Har-Noy thinks that the “Mirror EffectTM” may start an entirely new field of cancer therapy.


Dr. Michael Har-Noy of Immunovative Therapies, Ltd. is Patenting Valuable Technology

18 Apr

Traditional techniques of cancer therapy, such as surgery, radiation, and chemotherapy, cannot eliminate every metastatic malignant cell in the body. Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd, an Israeli biotechnology firm, says, however, that the immune system can be manipulated do just that. Dr. Michael Har-Noy indicates that a real cure could result if one could direct a patient’s own immune cells to eradicate malignant tumors.

Dr. Michael Har-Noy of Immunovative Therapies, Ltd. has formulated a proprietary process he which he calls the “Mirror EffectTM. The Mirror EffectTM represents a significant advance in our ability to eliminate cancer cells via the immune system and to neutralize the malignant tumor’s ability to evade this response. The Mirror EffectTM technology may stimulate the creation of a new field of cancer treatment. Dr. Michael Har-Noy says that by properly patenting the Mirror EffectTM, Immunovative Therapies, Ltd. could create a hugely profitable business.

Dr. Michael Har-Noy and his colleagues at Immunovative Therapies, Ltd. are working with their patent lawyers to build a portfolio that protects the entire scope of the Mirror EffectTM and defines its use to guide the immune system to treat some of medicine’s the most difficult conditions. Dr. Michael Har-Noy adds Immunovative Therapies, Ltd.’s patent portfolio will not only protect the company’s products and manufacturing methods but may also create a new industry based on immune manipulation as a medical treatment.

Ultimately, says Dr. Michael Har-Noy, Immunovative Therapies, Ltd.’s patent portfolio will probably change modern cancer treatment. Dr. Michael Har-Noy believes that the potential value of this technology is limitless.